[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-455683-105":59,"doc-detail-455683-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cancer-science-in-this-issue-volume-117-issue-1-january-2026","Cancer Science - In This Issue - Volume 117 - Issue 1 - January 2026","","Issue overview covering three research highlights in Cancer Science (Volume 117, Issue 1, January 2026). The first study addresses pancreatic ductal adenocarcinoma by combining immune checkpoint inhibitors with a CD40 agonist antibody, improving antitumor immunity and shrinking tumors in a murine model. The second presents an immunohistochemistry-based classification for BRAFV600E-mutant colorectal cancer, matching gene-expression categories and suggesting clinically relevant treatment implications. The third introduces mechanisms in liver cancer-associated fibroblasts involving lncDILC downregulation and a miR-6071-ZNF395 regulatory axis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-science-in-this-issue-volume-117-issue-1-january-2026/455683/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-science-in-this-issue-volume-117-issue-1-january-2026/455683.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-08","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What combination therapy is tested in the pancreatic cancer mouse model?","Question",{"text":112,"@type":113},"The study combines standard immune checkpoint inhibitors with a CD40 agonist antibody to strengthen antitumor immune activity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the colorectal cancer study classify BRAFV600E-mutant tumors?",{"text":117,"@type":113},"It uses immunohistochemistry markers to create an iBM1/iBM2 grouping that aligns with the original gene-expression classification.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is lncDILC downregulation important in liver cancer-associated fibroblasts?",{"text":121,"@type":113},"The work links lncDILC downregulation to pro-invasive conversion through a miR-6071-ZNF395 axis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},455683,1791450837,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":39},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Cancer Science  \nIN THIS ISSUE  OPEN ACCESS   \nIn This Issue  \nVolume 117, Issue 1, January 2026  \nA Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model  \nPancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal forms of cancer, with a five-year survival rate of only 13% . A major hurdle in treating PDAC is that the tumors are immunologically “cold.” They build a fortress of dense scar tissue (fibrosis) that blocks the immune system from entering, rendering modern breakthrough drugs like immune checkpoint inhibitors (ICIs), which work wonders in cancers like melanoma, largely ineffective for the patients. ICIs  \ntreat cancers by blocking certain proteins that function like“brakes” on the immune cells.  \nTo overcome this, Ichikawa et al. engineered a sophisticated new mouse model using genetic engineering approaches. Two genes commonly associated with PDAC, Kras and Trp53, were targeted. The Kras gene was mutated, and the Trp53 gene was also mutated in the mouse model. Unlike previous models, the new version accurately recreates the disease characteristics and the strong resistance to immune checkpoint blockade seen in patients, providing a realistic platform to test new therapeutic drugs and study the underlying mechanisms involved in the disease progression.  \nThe study combined standard ICIs (which remove the “brakes”on T cells) with a CD40 agonist antibody. This antibody activates antigen-presenting cells by stimulating the CD40 pathway. The CD40 agonist antibody had only modest effects when used by itself. The combination was more powerful in treating PDAC in the newly developed mouse model. The tumors shrank significantly, mice lived longer, and the immune environment within the tumors shifted from “cold” and suppressive to “hot”and active. The therapy improved the migration of the immune system cells called the dendritic cells to the lymph nodes, enhanced T cell activation, reduced immunosuppressive signals, and even decreased markers associated with tumor-promoting macrophages.  \nOverall, their study suggests that combining CD40 activation with checkpoint blockade could be a promising new strategy for patients who currently have few therapeutic options.  \n[https://onlinelibrary.wiley.com/doi/full/10.1111/cas.70246](https://onlinelibrary.wiley.com/doi/full/10.1111/cas.70246)  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.  \nCancer Science, 2026; 117:5–7 5  \n[https://doi.org/10.1111/cas.70303](https://doi.org/10.1111/cas.70303)  \nA Robust Immunohistochemistry-Based Classification for BRAFV600E-Mutant Colorectal Cancer With Clinical Implications  \nPrecision medicine is rapidly replacing the traditional “one size fits all” approach in cancer care. Specific changes in genes—called mutations—can help predict how a cancer behaves and which treatments are likely to work. However, the genomesequencing tests needed to identify these differences are costly, time-consuming, and not routinely available in most hospitals.  \nColorectal cancer (CRC) is a major cancer of the large intestine, and about 5%–10% of cases carry a mutation in the BRAF gene, most commonly BRAF V600E. Even among tumors with this same mutation, behavior can differ depending on which genes are active. Earlier research classified these tumors into two groups: BM1, marked by a process called epithelial–mesenchymal transition (EMT) that helps cancer cells spread and by strong immune activation; and BM2, characterized by increased cell-cycle activity and altered metabolism. These groups respond differently to treatment, with BM1 generally having poorer outcomes.  \nResearchers at Harbin Medical University in China ","cbCaisvTqR8P8nPu","https://ap.wps.com/l/cbCaisvTqR8P8nPu","pdf",1334845,"English","# In This Issue\n## Volume 117, Issue 1, January 2026\n## A Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model\n## A Robust Immunohistochemistry-Based Classification for BRAFV600E-Mutant Colorectal Cancer With Clinical Implications\n## lncDILC Downregulation in Liver Cancer-Associated Fibroblasts Drives Pro-Invasive Conversion via a miR-6071-ZNF395 Axis","[{\"question\":\"What combination therapy is tested in the pancreatic cancer mouse model?\",\"answer\":\"The study combines standard immune checkpoint inhibitors with a CD40 agonist antibody to strengthen antitumor immune activity.\"},{\"question\":\"How does the colorectal cancer study classify BRAFV600E-mutant tumors?\",\"answer\":\"It uses immunohistochemistry markers to create an iBM1/iBM2 grouping that aligns with the original gene-expression classification.\"},{\"question\":\"Why is lncDILC downregulation important in liver cancer-associated fibroblasts?\",\"answer\":\"The work links lncDILC downregulation to pro-invasive conversion through a miR-6071-ZNF395 axis.\"}]","Cancer Science - In This Issue - Volume 117 - Issue 1 - January 2026 | PDF",1790743870]